Mirum Pharmaceuticals (NASDAQ: MIRM) Sees Price Target Boosted to $195 Following Key Drug Approvals and Pipeline Success

Font: Financial Modeling Prep  • Sep 28, 2026

• Analyst firm H.C. Wainwright raised its price target for Mirum Pharmaceuticals to $195.00 from $140.00, indicating strong confidence in the biopharmaceutical company's future.
• The company's drug Brelovitug met its main goal in the Phase 3 AZURE-1 study for Chronic Hepatitis Delta Virus, a significant drug development pipeline success.
• Mirum Pharmaceuticals, in partnership with Incyte (NASDAQ: INCY), received U.S. FDA approval for Atebrioz™ (zilurgisertib) for Fibrodysplasia Ossificans Progressiva, opening a new revenue stream.

Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading biopharmaceutical company that focuses on developing and commercializing treatments for rare liver diseases. On September 28, 2026, analyst firm H.C. Wainwright increased its price target for Mirum Pharmaceuticals to $195.00. This is a significant raise from its previous target of $140.00, suggesting strong confidence in the company's future performance and investment potential.

This optimism follows major positive news from the company's drug development pipeline. As highlighted by Business Wire, Mirum Pharmaceuticals announced that its Phase 3 AZURE-1 study for the drug Brelovitug met its main goal. This study is focused on treating Chronic Hepatitis Delta Virus, and the positive result is a key step toward potential regulatory approval.

Further strengthening its market position, Mirum Pharmaceuticals also received U.S. FDA approval for its drug Atebrioz™ (zilurgisertib), a development shared with its partner Incyte (NASDAQ: INCY). This approval allows the drug to be used for treating Fibrodysplasia Ossificans Progressiva, a rare bone disease, in both adult and pediatric patients, opening up a new revenue stream for the biotech firm.

Despite these positive developments, Mirum Pharmaceuticals shares are currently trading at $87.10, a decrease of 2.90% for the day. The stock's price has moved between $84.89 and $90.00 during the session. The new analyst target of $195.00 represents a substantial potential increase from its current trading price, highlighting significant upside potential.

The company has a market capitalization of approximately $5.31 billion. Market capitalization is the total market value of a company's outstanding shares. Over the past 52 weeks, Mirum Pharmaceuticals' stock performance has seen its shares trade as high as $130.00 and as low as $63.23, showing significant price movement over the last year.